---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-027867"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-07-15T23:59:59+00:00"
generated_at: "2026-05-31T20:49:47.076709+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics announces 1-for-10 reverse stock split effective July 15, 2024

## Summary
- Reverse stock split at a 1-for-10 ratio, effective 12:01 a.m. ET on July 15, 2024.
- Stockholder approval obtained at special meeting on June 6, 2024; Board set ratio at 1:10.
- No fractional shares will be issued; fractional shares rounded up to the next whole number.
- Authorized shares of common stock remain unchanged at 330,000,000 shares.
- Trading symbol remains CLDI; new CUSIP number for common stock is 320703309.

## SEC filing metadata
- accession: 0001493152-24-027867
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-07-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224027867/0001493152-24-027867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224027867/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-027867
- JSON: https://secwatch.observer/filing/0001493152-24-027867.json
- Plain text: https://secwatch.observer/filing/0001493152-24-027867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.